Bolivian Yungas Coffee (Coffea arabica 'Bolivian Yungas')

Bolivian Yungas Coffee (Coffea arabica 'Bolivian Yungas') is a specialty arabica cultivar grown in Bolivia's Yungas region, containing approximately 1.3–1.4% caffeine as its primary bioactive compound. Caffeine exerts its effects chiefly by antagonizing adenosine A1 and A2A receptors in the central nervous system, promoting alertness and reducing perceived fatigue.

Origin & History

Bolivian Yungas Coffee is a cultivar variant of Coffea arabica grown in the mountainous Yungas region of Bolivia, where smallholder farms (1-8 hectares) produce 85-95% of the country's primarily organic Arabica coffee. The beans undergo natural processing methods yielding green coffee with balanced cup profiles featuring light to medium body, mild acidity, and notes of citrus, dried fruit, and caramel (SCA scores 86-87).

Historical & Cultural Context

Bolivian Yungas Coffee lacks documented historical use in traditional medicine systems according to the research results. It is primarily recognized as a modern specialty crop from Bolivia's Yungas region, with production focused on commercial organic and fair trade markets rather than medicinal applications.

Health Benefits

• No clinical health benefits documented - no human trials, RCTs, or meta-analyses specific to Bolivian Yungas Coffee were identified in the research
• General C. arabica composition suggests caffeine content (1.3-1.4%) may support alertness, though no Yungas-specific evidence exists
• Rich in carbohydrates (22-24%) and proteins (12-13%) based on general C. arabica data, but no health outcomes studied
• Contains lipids (6-11%) including linoleic and palmitic acids, though biomedical effects not established for this cultivar
• Low heavy metal and mycotoxin levels in related C. arabica products suggest safety profile, but no therapeutic benefits proven

How It Works

Caffeine, the principal bioactive in Bolivian Yungas Coffee, competitively antagonizes adenosine A1 and A2A receptors, preventing the accumulation of sleep-promoting adenosine and elevating dopaminergic and noradrenergic signaling. Chlorogenic acids present in arabica cultivars inhibit glucose-6-phosphatase and modulate the Nrf2/ARE antioxidant pathway, potentially supporting glycemic regulation and reducing oxidative stress. Diterpenes such as cafestol and kahweol interact with pregnane X receptor (PXR) and may influence bile acid metabolism and hepatic enzyme activity.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses specific to Bolivian Yungas Coffee (C. arabica 'Bolivian Yungas') were identified in the search results. The available research focuses solely on agronomic characteristics, chemical composition of general C. arabica, and safety assessments of related coffee products like cascara, with no PMIDs or clinical outcomes reported for this specific cultivar.

Clinical Summary

No clinical trials, randomized controlled studies, or meta-analyses specific to Bolivian Yungas Coffee have been identified in the published literature. Evidence for its physiological effects must be extrapolated from broader Coffea arabica research, where caffeine doses of 3–6 mg/kg body weight have demonstrated improvements in reaction time, vigilance, and endurance performance in human trials. Chlorogenic acid research in general arabica coffee suggests modest reductions in fasting blood glucose (approximately 0.5–1.0 mmol/L) at intakes of 400–800 mg/day, based on pooled data from multiple RCTs. The absence of cultivar-specific data means efficacy and optimal dosing for Bolivian Yungas Coffee remain scientifically unestablished.

Nutritional Profile

Based on general Coffea arabica green bean composition (no Yungas-specific analytical data available): **Macronutrients (per 100g green beans):** Carbohydrates 50-55g (including sucrose 6-9g, polysaccharides 40-45g), Proteins 11-13g, Lipids 12-18g (predominantly linoleic acid ~44% and palmitic acid ~34% of total fatty acids), Dietary fiber 25-33g (galactomannans and arabinogalactans). **Bioactive compounds:** Caffeine 1.0-1.4g/100g (1,3,7-trimethylxanthine), Chlorogenic acids (CGAs) 6-8g/100g (predominantly 5-caffeoylquinic acid, 3-caffeoylquinic acid, and 4-caffeoylquinic acid), Trigonelline 0.6-1.2g/100g, Kahweol 0.1-0.6g/100g, Cafestol 0.3-0.7g/100g (both diterpene esters found in the lipid fraction). **Minerals:** Potassium 1500-1800mg/100g, Magnesium 150-200mg/100g, Phosphorus 150-200mg/100g, Calcium 80-130mg/100g, Iron 3-10mg/100g, Zinc 3-5mg/100g, Manganese 2-4mg/100g. **Vitamins:** Niacin (B3) 15-20mg/100g (partially liberated from trigonelline during roasting), traces of riboflavin (B2), thiamine (B1), and tocopherols (vitamin E, ~10-20mg/100g in lipid fraction). **Roasted bean/brewed coffee notes:** Roasting degrades 50-70% of CGAs and ~50-80% of trigonelline while generating melanoidins (25% of roasted bean dry weight) with antioxidant properties; a standard brewed cup (~240mL) typically delivers 80-120mg caffeine, 70-200mg CGAs, 20-80mg potassium, and trace minerals. **Bioavailability notes:** Chlorogenic acids are ~33% absorbed in the small intestine with the remainder metabolized by colonic microbiota to hippuric, ferulic, and dihydrocaffeic acids; caffeine is nearly 100% bioavailable with rapid absorption (Tmax ~30-60 min); diterpenes (cafestol/kahweol) are largely removed by paper filtration but present in unfiltered preparations (French press, espresso); mineral bioavailability may be reduced by CGA chelation of iron and zinc. Yungas-region cultivation (1200-1800m altitude, humid subtropical cloud forest) may influence CGA and sucrose concentrations due to slower cherry maturation at altitude, but no cultivar-specific compositional analyses have been published.

Preparation & Dosage

No clinically studied dosage ranges are available for Bolivian Yungas Coffee in any form (extract, powder, or standardized preparations), as no human trials were conducted. General C. arabica green beans contain 1.32-1.42% caffeine, but no standardization protocols or therapeutic dosing guidelines exist for this cultivar. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified due to lack of clinical research

Safety & Interactions

Caffeine intakes exceeding 400 mg/day (roughly 4–5 standard cups) are associated with insomnia, tachycardia, anxiety, and gastrointestinal distress in healthy adults, per European Food Safety Authority guidance. Caffeine inhibits CYP1A2 metabolism and can potentiate the effects of stimulant medications, increase theophylline plasma levels, and reduce the efficacy of adenosine-based antiarrhythmics. Pregnant individuals are advised to limit caffeine to under 200 mg/day, as higher intakes are associated with increased risk of low birth weight and miscarriage. Individuals with hypertension, arrhythmias, anxiety disorders, or gastroesophageal reflux disease should consult a healthcare provider before regular consumption.